Few biotech companies have made more noise than Viking Therapeutics (VKTX 3.61%) this year, and that's saying something. The drugmaker had been a relatively small and unknown player in the industry.

In May, Viking announced encouraging results from a phase 2b study of VK2809 in treating non-alcoholic steatohepatitis (NASH). Both weight loss and NASH represent huge potential markets for Viking.